Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
This study has been withdrawn prior to enrollment.
(Low accrual)
Sponsor:
New York University School of Medicine
Collaborator:
GlaxoSmithKline
Information provided by:
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00659399
First received: April 10, 2008
Last updated: October 20, 2009
Last verified: October 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Study Status: | This study has been withdrawn prior to enrollment. |
|---|---|
| Estimated Study Completion Date: | November 2010 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |